(Q48023783)

7 February 2018

title

The burden of COPD in Canada: results from the Confronting COPD survey (English)

1 reference

7 February 2018

0 references

Chapman KR

1

1 reference

7 February 2018

Bourbeau J

series ordinal

2

1 reference

7 February 2018

Rance L

series ordinal

3

1 reference

7 February 2018

publication date

1 March 2003

1 reference

7 February 2018

published in

Respiratory Medicine

1 reference

7 February 2018

volume

97 Suppl C

1 reference

7 February 2018

page(s)

S23-31

1 reference

7 February 2018

Trends in the epidemiology of COPD in Canada, 1980 to 1995. COPD and Rehabilitation Committee of the Canadian Thoracic Society.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Gender bias in the diagnosis of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Economic analysis of the Confronting COPD survey: methodology

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Physician perceptions and management of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2980022-7

7 January 2021

10.1016/S0954-6111(03)80022-7

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018